2. UroToday Home
  3. Video Lectures

Localized Prostate Cancer Videos

CAN-2409 in Localized Prostate Cancer: Protocol, Outcomes, and Patient Perspective - Mark Garzotto & Tom Hulsey
PROTEUS Trial: Neoadjuvant Apalutamide and Androgen Deprivation Therapy in High-Risk Localized Prostate Cancer - Mary-Ellen Taplin
Hydrogel Spacer Placement for Prostate Radiotherapy: A Urology Residency Training Experience - Zachary Klaassen
CAN-2409 with Valacyclovir and Radiation for Localized Prostate Cancer - Mark Garzotto
PEACE-2 Trial of Cabazitaxel with ADT and Radiotherapy in Very High-Risk Localized Prostate Cancer - Karim Fizazi
Salvage Radiotherapy in Prostate Cancer: Weighing the Role of Added Hormonal Therapy - Valerie Fonteyne
Testosterone Recovery Dynamics After Short-Term ADT for Localized Prostate Cancer - Bertrand Tombal
Balancing Treatment Intensification and Quality of Life in Elderly Prostate Cancer Patients - Rana McKay
Comparing Risk Models to Guide Biopsy Decisions for Intermediate Prostate MRI Findings - Nathan Perlis
CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized Prostate Cancer - Anna Wilkins
GUNS Trial Examines Biomarker‑Selected Neoadjuvant Approaches in High‑Risk Prostate Cancer - Martin Gleave
Rectal Spacers in Prostate Radiotherapy: Balancing Efficacy, Safety, and Patient Experience - Michael Greenberg & Daniel Welchons
Cluster-Randomized Trial Targets Barriers to Mainstream Germline Testing for Veterans - Daniel Kwon
Evolving Strategies in Localized Prostate Cancer: From Diagnosis to Recurrence and Future Directions - Neal Shore
Co-PSMA Trial Explores Tracer for Detecting Recurrence After Radical Prostatectomy - Louise Emmett
The Co-PSMA Trial: Comparing PSMA PET Tracers in Biochemically Recurrent Prostate Cancer - Louise Emmett
PSA Control After Treatment Suspension: EMBARK Data at 36 Months - Neal Shore
Salvage Radiotherapy Intensification Tested in Men with High-Risk Biochemical Recurrence - Edwin Posadas
ASCENDE-RT Trial Reports 15-Year Survival Update in High-Risk Prostate Cancer - Scott Tyldesley
PAM50 Intrinsic Subtyping and Salvage Therapy Decisions After Prostatectomy - Jonathan Tward
Integrating Genomic Prognostic and Hallmark Signatures to Predict Outcomes in Active Surveillance - Kevin Shee
Correlation Between Genomic Classifier Scores and Upfront Treatment Selection in Localized Prostate Cancer: A Real-World U.S. Population-Based Cohort Study - Michael Leapman
REVELUTION Trial: A Comparative Study of GnRH Agonist and Antagonist on Coronary Plaque in Prostate Cancer - Sagar Patel
Study Examines the Path to Proficiency in Prostate MRI Interpretation for Trainees - Dominik Deniffel & Thomas Herrmann
Analysis of a Posterior Surgical Technique in Robotic Assisted Radical Prostatectomy - Jim Hu
Study Investigates an AI-Powered Prognostic Test in Salvage Radiation Therapy Patients - Paul Nguyen
Coronary Atherosclerosis Findings from the REVELUTION Trial of Leuprolide and Relugolix - Avirup Guha & Sagar Patel
PI-CAI Study Evaluates AI for Detecting Prostate Cancer on MRI - Anindo Saha
Secondary Analysis of ProtecT Trial Evaluates Impact of Cribriform Morphology on Metastasis - Nikita Sushentsev
PSMACare: Early Lutetium RLT in High-Risk nmCRPC - Fred Saad
DADSPORT Meta-Analysis Reports on Hormone Therapy with Post-Prostatectomy Radiotherapy - David Fisher
The Phase III ENZARAD Trial: Enzalutamide with Radiation and ADT in High-Risk Prostate Cancer - Paul Nguyen
EMBARK Trial Reports Overall Survival Benefit for Enzalutamide with ADT in High-Risk Non-Metastatic Prostate Cancer - Stephen Freedland
ERSPC 23-Year Update: Long-Term Benefits of PSA Screening - Monique Roobol
Patient-Reported Outcomes in the NRG-GU005 Prostate Cancer Trial - James Yu
Ten-Year Outcomes of the PCS5 Trial for High-Risk Prostate Cancer Presented - Tamim Niazi
Pre-ESMO 2025 Highlights - Rashid Sayyid & Zachary Klaassen
Randomized Trial of NeuroSAFE Technique in Radical Prostatectomy for Erectile Function - Eoin Dinneen & Ricardo Almeida-Magana
NRG-GU005 Trial Compares SBRT and Hypofractionated IMRT for Prostate Cancer - Rodney Ellis
Evaluating the Use of Lymph Node Dissection During Radical Prostatectomy - Fernando Pablo Secin & Juan Carlos Vélez Román
Using PSMA PET in Primary Staging and Recurrence - Armando Juliao
AI's Role in Prostate Cancer Diagnosis, Imaging, and Pathology - Matthew Cooperberg
Biomarker Applications in Localized and Advanced Prostate Cancer - Julian Chavarriaga
First Cross-Continent Robotic Prostatectomy Performed Using Tele-Surgery - Vipul Patel
CAN-2409 + Radiation Improves Disease-Free Survival in Prostate Cancer Patients - Angela Jia
ICECaP Meta-Analysis Explores Docetaxel's Benefit in Very High-Risk Prostate Cancer - Praful Ravi
Neoadjuvant and Adjuvant ARPIs in High-Risk Localized Prostate Cancer - Robert Reiter
Neoadjuvant Niraparib in High-Risk Localized Prostate Cancer with DNA Repair Gene Alterations - Marc Dall'Era
Real-World Prostate Cancer Treatment Patterns in Colombia - Ray Manneh Kopp
Emerging Prognostic Value of Molecular Imaging in Prostate Oncology - Wolfgang Fendler
Persistent PSA After Prostatectomy: Timing and Mortality Risk Implications, Journal Club - Rashid Sayyid & Zachary Klaassen
Multimodal AI Test Predicts Prostate Cancer Metastasis and Treatment Response - Timothy Showalter
Treatment Intensification Strategies for High-Risk Prostate Cancer Patients - Aaron Berger
Optimizing Prostate Biopsy Specimens for Improved Pathological Diagnosis - Daniel Wiener
The Details Are in the Core: Advancing Prostate Tissue Collection - James Wysock
Advanced Imaging for Focal Therapy in Intermediate Risk Prostate Cancer - Matthew Cooperberg
Multimodal Artificial Intelligence Concordance Between Whole-Mount Specimens and Tissue Microarrays in Prostate Cancer Analysis - Adam Dicker
Estrogen Patches Combined with AR Pathway Inhibitors Show Promise in Prostate Cancer Management - Nicholas James
Radiation Therapy vs Surgery Outcomes in High-Risk Localized Prostate Cancer Patients - Soumyajit Roy
Gut Microbiome and Prostate Cancer: How Diet Impacts Disease Progression - Robert Thomas
PORTOS Biomarker Guides Radiation Dose Escalation in Prostate Cancer Treatment - George Zhao & Alan Dal Pra
ARASTEP Trial Tests Darolutamide and ADT in High-Risk Biochemically Recurrent Prostate Cancer - Alicia Morgans
Combining Genomic Classifier and Digital Pathology Artificial Intelligence in Prostate Cancer Risk Stratification - Daniel Spratt
Canonical Androgen Response Elements in Prostate Cancer Growth Suppression - Christopher Barbieri
Genomic Classifier Decipher® Guides Treatment Intensification in Post-Prostatectomy Patients - Phuoc Tran
Universal Germline Genetic Testing for Prostate Cancer Patients - Neal Shore & Sarah Young
Urinary Incontinence in Gay and Bisexual Prostate Cancer Survivors - Kristine Talley
Overtreatment of Prostate Cancer Persists in Men with Limited Life Expectancy - Timothy Daskivich
Study Uncovers AR-Positive Stromal Cells’ Role in Prostate Cancer Microenvironment - Ece Eksi
The Proteogenomics of Prostate Cancer Radioresistance - Roni Haas
Smart Technology Advances Erectile Health Monitoring and Care - Amy Pearlman
AI-Derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer - Martin King & David Yang
Heterogeneous Genetic Architectures of Prostate Cancer Susceptibility in Sub-Saharan Africa - Timothy Rebbeck
Online Platform Maps Theranostic Trials Worldwide for Patients and Physicians - Luke Nordquist
CLARIFY Trial: Multiday 64Cu-SAR-bisPSMA PET Scans Refine Prostate Cancer Assessment - Luke Nordquist
'Unfavorable Histology’ Classification Aims to Reduce Unnecessary Treatment, Discussion
'Unfavorable Histology’ Classification Aims to Reduce Unnecessary Treatment, Journal Club - Jesse McKenney, Jane Nguyen, & Cornelia Ding
Pelvic Muscle Rehabilitation after Radical Prostatectomy - Diane Newman
Integrating Genomic Testing with MRI Enhances Stratification of Surveillance Patients - Eric Kim & Mark Sultan
Traction Therapy Helps Men Regain Penile Length After Prostate Cancer Treatment - Amy Pearlman
Penile Rehabilitation After Prostate Cancer Treatment - Amy Pearlman
Challenges in Defining High-Risk Localized Prostate Cancer for Optimal Treatment "Presentation" - Martin Gleave
What is the Role of DRE in the Modern Imaging Era? "Presentation" - Declan Murphy
Regional Lymph Node Staging for High-Risk and Locally Advanced Prostate Cancer – What Should be the Standard? “Presentation” - Jochen Walz
Genomic Classifiers and Artificial Intelligence (AI) as Predictors for Treatment Benefit "Presentation" - Daniel Spratt
Impact of Imaging and Biopsy Techniques on Treatment Decisions "Discussion"
Radiation Therapy Schedules and Fields for Highrisk and Locally Advanced Prostate Cancer "Presentation" - Neha Vapiwala
Surgery as Radical Local Treatment (As Part of a Multimodality Approach) "Presentation" - Alberto Briganti
Radiation Therapy as Radical Local Treatment (As Part of a Multimodality Approach) "Presentation" - Piet Ost
How to Select Patients for Adjuvant Therapy After Radical Prostatectomy and How to Treat Them? "Presentation" - Jason Efstathiou
Surgery vs Radiation vs Multimodal Prostate Cancer Treatment "Discussion"
How to Manage Patients with PSA Persistence Following Radical Prostatectomy? "Presentation" Derya Tilki
How to Select Patients with Biochemical Relapse in Whom Salvage Radiation Therapy Can be Postponed? "Presentation" - Barbara Alicja Jereczek-Fossa
Which Patients with High-Risk First BCR After Radical Prostatectomy are Candidates for Systemic Therapy Alone Without Local Salvage RT? "Presentation" - Bertrand Tombal
In Patients Who Receive Salvage Radiation Therapy For BCR, Who Needs Additional Systemic Therapy, What and For How Long?" Presentation" - Daniel Spratt
Timing of Salvage Radiotherapy in Recurrent Prostate Cancer Management "Discussion"
In Patients with BCR and Positive Lesion(s) in the Pelvis – Stereotactic or Whole Pelvis RT? "Presentation" - Paul Nguyen
Managing Gynecomastia in ARPI Prostate Cancer Treatment "Presentation" - Neal Shore
Second BCR (Without Correlate on NGI) After Salvage Radiation And/or After Metastases Directed Therapy: How to Manage These Patients "Presentation" - Ray McDermott
Treatment for Biochemical Recurrence/PSA Persistence "Discussion"
Update on the IRONMAN Project "Presentation" - Alicia Morgans
Cardiovascular Complications in Advanced Prostate Cancer – How to Prevent Them and How to Monitor Patients? "Presentation" - Thomas Suter
Hot Flushes – How Can We Help Our Patients? "Presentation" - Anthony Joshua
Lancet Commission on Prostate Cancer– the Forthcoming Surge in Prostate Cancer Raises Very Different Issues to the Ones We Face Today "Presentation" - Nicholas James
How Do We Maximize Use of Radiotherapy for Prostate Cancer in Africa "Presentation" - Omolara Aminat Fatiregun
How Do We Modify the Diagnostic Pathway to Deal with Rising Rates of Prostate Cancer in Africa? "Presentation" - Onyeanunam Ngozi Ekeke
Dealing with Inequality - the Promise and Pitfalls for Social Media and AI for Prostate Cancer in Disadvantaged Populations "Presentation" - Stacy Loeb
How to Deal with the Projected Rise of Prostate Cancer Cases in the Chinese Healthcare System "Presentation" - Dingwei Ye
Global Cancer Care Challenges & Solutions in Developing Nations "Discussion"
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
Exercise Benefits In Prostate Cancer Active Surveillance - Dong-Woo Kang
Hypofractionated Radiotherapy Efficacy for Post-Prostatectomy Patients - Asunción Hervás
Optimizing Post-Operative Care in Robotic Prostatectomy Same-Day Discharge - Brian Lane
PACE-C Trial Results: SBRT vs Moderate Hypofractionation for High-Risk Prostate Cancer - Alison Tree
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
Radiation Therapy Options for Localized Prostate Cancer Compared in Major Trial - Jason Efstathiou
Proton Therapy vs IMRT in Prostate Cancer PARTIQoL Trial - Jason Efstathiou
PATCH Trial Evaluates Transdermal Estradiol in Non-Metastatic Prostate Cancer - Duncan Gilbert
PARTIQoL Trial: Proton Therapy vs IMRT for Localized Prostate Cancer - Jason Efstathiou
Rising Out-of-Pocket Costs in Prostate Cancer Screening: A Growing Concern - Arnav Srivastava
Transperineal vs Transrectal Prostate Biopsy: Trial Findings and Discussion - Badar Mian
Transperineal vs Transrectal Prostate Biopsy: Clinical Trial Findings - Badar Mian
Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett
CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET - Neal Shore
Welcome and Background Cancer or Not Cancer "Presentation" - Scott Eggener
Rationale for Nomenclature Change Gleason Grade 1 Cancer "Presentation" - Matthew Cooperberg
Reservations About a Nomenclature Change for Gleason Grade 1 Prostate Cancer "Presentation" - Adam Kibel
What is in a Name? Inadvertent Harm from the Designation and Label of 'Cancer' "Presentation" - Laura Esserman
Grade Group 1 Prostate Cancer: A Pathologist's Case for Cancer Classification 'Con' "Presentation" - Gladell Paner
Grade Group 1 Prostate Cancer: A Pathologist's Case for Cancer Classification 'Pro' "Presentation" - Theodorus van der Kwast
Prostate Cancer Classification Dilemma: Lessons from Breast and Colorectal Tumors "Presentation" - Jeffry Simko
Prostate Cancer Biopsy Sampling: Challenges in Grade Group 1 Classification "Discussion" - Lawrence True
Rethinking Cancer Treatment: Lessons from Breast to Prostate Cancer "Presentation" - Alastair Lamb
Where to Draw the Line? The Spatial Molecular Continuum from 'Normal' to GG1 to GG2 Prostate Cancer "Presentation" - Alastair Lamb
Active Surveillance in Prostate Cancer: Rethinking Gleason Grade Group 1 "Presentation" - Daniel Lin
Active Surveillance Challenges in Prostate Cancer Management "Presentation" - Laurence Klotz
MRI Impact on Grade Group 1 Prostate Cancer Detection in Australia "Presentation" - Declan Murphy
Active Surveillance vs. Watchful Waiting in Prostate Cancer Management "Presentation" - Caroline Moore
Prostate Cancer Risk Assessment: Beyond Gleason Pattern Ratios "Presentation" - Andrew Vickers
Modeling Prostate Cancer: Rethinking Grade Group 1 Classification "Presentation" - Ruth Etzioni
The Debate on Prostate Cancer Grading: Addressing Underdiagnosis and Overdiagnosis Concerns "Presentation" - Andrew Vickers
Rethinking Prostate Cancer Classification: The Cribriform Pattern Debate "Discussion"
Alternative Payment Models in Prostate Cancer: Nomenclature Impact "Presentation" - CJ Stimpson
Active Surveillance in Europe: Challenges and Heterogeneity "Presentation" - Derya Tilki
Prostate Cancer in Africa: Pathology Outcomes and Risk Profiles "Presentation" - Mohamed Jalloh
Prostate Cancer Diagnosis: MRI vs. Systematic Biopsy "Discussion"
Racial Disparities in Prostate Cancer Active Surveillance Outcomes "Presentation" - Quoc-Dien Trinh
Prostate Cancer Risk Assessment: Addressing Racial Equity Concerns "Discussion"
Renaming Gleason 6 Prostate Cancer: Patient Perspectives and Impacts "Presentation" - Howard Wolinsky
Patient Perspectives on Prostate Cancer: Quality of Life and Treatment Decisions "Presentation" - Leszek Izdebski
CDC's Role in Advancing Prostate Cancer Active Surveillance Research "Presentation" - Ingrid Hall
Prostate Cancer Nomenclature: Impact on Screening Guidelines "Presentation" - Timothy Wilt
Rethinking Grade Group 1 Prostate Cancer: UK's Paradigm Shift "Presentation" - Hashim Ahmed
Rethinking Prostate Cancer Diagnosis: UK vs US Approaches "Discussion"
Prostate Cancer Markers: Challenges in Differentiating Low-Risk Cases "Discussion"
Genomics in Prostate Cancer: Limitations in Active Surveillance "Presentation" - Felix Feng
Redefining Prostate Cancer: The Debate on Grade Group 1 Classification "Discussion"
Reclassifying Prostate Cancer: Clinical Implications of Grade Group 1 Nomenclature Change "Discussion"
Prostate Cancer Nomenclature Change: Impact on Advocacy and Patient Care "Discussion"
Prostate Cancer Nomenclature Change: Societal and Clinical Implications "Discussion"
Prostate Cancer Management: Rethinking Active Surveillance and Nomenclature "Discussion"
AI-Powered Prostate Cancer Grading Predicts Active Surveillance Outcomes - Cornelia Ding
Exploring Financial Toxicity and Cultural Differences in Prostate Cancer Active Surveillance "Discussion"
VA's Million Veterans Program Reveals Crucial Genetic Data for Prostate Cancer Treatment - Bruce Montgomery
Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen
2024 NCCN Guidelines: Simplifying the Management of Very Low-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
MAST Trial: Investigating Metformin's Role in Prostate Cancer Active Surveillance - Anthony Joshua
Prostate Cancer Knowledge and Screening Barriers in Northern Tanzania: A Community-Based Study - Blandina Mmbaga & Nicholas Ngowi
Behavioral Interventions for Mitigating ADT Side Effects in Prostate Cancer - Brian Gonzalez
Automated Identification of Key Steps in Robotic-Assisted Radical Prostatectomy Using Artificial Intelligence - Abhinav Khanna
Testosterone Recovery After ADT: Timing, Predictive Factors, and Clinical Implications - Pierre Blanchard
Moonshot Initiative Funds Study on PSA-Based Risk-Stratified Prostate Cancer Screening - Siobhan Sutcliffe
Staging High-Risk Prostate Cancer with PSMA PET: Strengths and Pitfalls - Irene Burger
A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy - Beyond the Abstract
Novel 18-Gene Urine Test Improves Detection of Clinically Significant Prostate Cancer - Jeffrey Tosoian
CEASAR Study Reveals Long-Term Quality of Life Outcomes for Localized Prostate Cancer Treatments - Daniel Barocas & Bashir Al Hussein Al Awamlh
PSMA PET & The Impact of the PRIMARY Trial "Presentation" - Louise Emmett
ProtecT Trial 15-Year Data Shows Low Prostate Cancer Mortality Across Therapies for Localized Disease, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg
Discussion Between Expert Clinicians and Patients on the ProtecT Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg
Radiation Outcomes Improve with Age in Localized Prostate Cancer - Mack Roach
How Mental Health Disorders Impact Treatment Decisions in Localized Prostate Cancer - Yaw Nyame & Joshua Cabral
Parsing the Evidence from the EMBARK Trial on a Promising New Drug Regimen in High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer - Matthew Cooperberg
PACE B Study Analysis: Acute and Late Toxicities in Prostate Cancer Radiotherapy - Ragu Ratnakumaran
The Prognostic Value of PSA Levels Post-Radiation in Prostate Cancer - Praful Ravi
Exploring Regional Variation in Genomic Testing and Imaging in Prostate Cancer - Michael S. Leapman
Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm Phase 2 Trial - Eugene Shenderov
Journal of Urology Open Plus - Revolutionizing Access and Innovation in Urology Research - John W. Davis
Improving Primary Prostate Cancer Diagnosis Through Risk Stratified Screening: a European Perspective - Sigrid Carlsson
Advancements in Prostate Cancer Screening: Inclusion of At-Risk Groups, Imaging & Biomarkers - An AUA Guidelines Update - Daniel Lin
Risk Assessment in Localized Prostate Cancer - Insights from Real-World Data and SEER Registry - Jim Hu
ProtecT Trial Reveals New Insights for Prostate Cancer Treatment: Implications for Low-Risk vs. High-Risk Patients - David Penson
15-Year Follow-Up of the ProtecT Trial: Discussing Results and Changes in Prostate Cancer Management, The ProtecT Trial - Oliver Sartor
Advancing Rectal Spacing in Prostate Cancer Radiation Therapy: The Benefits of Barrigel® - Neil Mariados
Improving MRI for Localized Prostate Cancer Diagnosis: The Need for a Standardized and Quantitative MRI Approach - Tyler Seibert
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases - Beyond the Abstract
Treatment-Specific Out-of-Pocket Costs for Patients Undergoing Localized Prostate Cancer Journal Club - Zachary Klaassen
Differences in Mental Health Outcomes According to the Treatment Received for Men Being Treated with Localized Prostate Cancer Journal Club - Zachary Klaassen
Using MRI to Safely Prevent Unnecessary Protocol-Advised Repeat Biopsy During Active Surveillance Journal Club - Zachary Klaassen
Comparing the Relative Benefits of Radiotherapy Dose Escalation ± Short-Term or Long-Term ADT as Treatment Intensification for Localized Prostate Cancer Journal Club - Zachary Klaassen
10-year Results DART 01-05, High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localized Prostate Cancer Journal Club - Zachary Klaassen
The Molecular Biology of Prostate Cancer - Christopher Barbieri
DNA Repair Genes Associated With Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
The Role of Imaging Before and After Diagnosis of Localized Prostate Cancer - Masoom Haider
A Probing Conversation on Prostate Cancer Diagnosis and the Potential of Liquid Biopsies and Polygenic Risk Scores - Sanoj Punnen
Deciding Against Active Surveillance: How Genomic Testing Impacted Treatment Decision-Making Among a Predominantly African American Population - Peter Gann and Adam Murphy
How Genomic Testing Impacts NCCN Risk Classification of Black Men with Low and Intermediate Risk Prostate Cancer - Andrew Winer
The ENACT Trial: Ezalutamide Monotherapy plus Active Surveillance vs Active Surveillance Alone in Patients with Low-Risk or Intermediate-Risk Prostate Cancer - Neal Shore
LuTectomy, a Single-Arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Radical Prostatectomy - Declan Murphy & Renu Eapen
Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin
Genomic Risk Classification in Localized Prostate Cancer - Matthew Cooperberg
Prostate Volume, Baseline Urinary Symptoms, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men with Localized Prostate Cancer, The CEASAR Study - Daniel Barocas
Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz
Active Surveillance for Patients With Intermediate-Risk Prostate Cancer - Stacy Loeb
Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp
The Benefit of ADT Treatment Intensification with Radiotherapy for Men with Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain & Christopher Dee
Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg
Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks
Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein
AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt
AI-derived Digital Pathology-Based Biomarkers in Localized Prostate Cancer - Felix Feng
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis
Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
NCCN Prostate Cancer Clinical Practice Guidelines on Risk Stratification for Clinically Localized Prostate Cancer – Christopher Wallis & Zachary Klaassen
Improving the Quality of Care for Men in Michigan With Prostate Cancer, the MUSIC Collaborative, a Focus on the G-MINOR and G-MAJOR Trials – Todd Morgan
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher® Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Prostate Cancer Screening and Shared Decision Making in the Veterans Health Administration - Stacy Loeb
PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu
Prostate Cancer Modeling: The CISNET Prostate Group - Ruth Etzioni
Relugolix vs. Traditional ADT: A Comparative Analysis in the Setting of Definitive Therapy for Localized Disease - Ashley Ross
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
How Can We Accelerate Clinical Trial Accrual in Localized Prostate Cancer? - Brian F. Chapin
Prostate Active Surveillance Study (PASS) - Daniel Lin
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener 
DASL-HiCAP (ANZUP1801): The Impact of Darolutamide on Standard Therapy for Localized Very High-risk Cancer of the Prostate - Christopher Sweeney
The Role of Neoadjuvant Therapy for Patients with Localized Prostate Cancer - Rana R. McKay
Active Surveillance for Low-Risk Prostate Cancer - Laurence Klotz and Peter Carroll
Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer - June Chan
Study of Baseline PSA Screening of Men (45 years old) - Peter Albers
Radiation Therapy Advances and Technology Overview - Daniel Spratt
Epidemiologic Outcomes of Prostate Cancer Patients Undergoing Active Surveillance - Sigrid Carlsson
Increasing Rates of Active Surveillance as the Standard of Care in Men with Low Risk Prostate Cancer- Matthew Cooperberg
ProVent Trial for Newly Diagnosed Prostate Cancer - Benjamin Lowentritt
Engagement in Long-Term Physical Activity and Lowering the Risk of Advanced Prostate Cancer - Lorelei Mucci
Focal Therapy: Ready or Not - Herbert Lepor
EXTEND, Phase 2 Trial Evaluating the Safety and Efficacy of Exercise Training in Men with Hormone Naïve Prostate Cancer - Mike Harrison
Long-Term Outcomes of Active Surveillance for Prostate Cancer - Interview with Sigrid Carlsson
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons
Active Surveillance: Who is the Right Patient? - Matt Cooperberg